Seattle Genetics: Q3 2015 Results (Seattle Genetics, Inc) - Oct 30, 2015 - Anticipated initiation of P1/2 trial for pre-conditioning or post-allogeneic transplant maintenance treatment in patients with AML in H1 2016; Anticipated initiation of P1/2 trial in combination with azacitidine in previously untreated myelodysplastic syndrome in H1 2016
Anticipated new P1/2 trial • Acute Myelogenous Leukemia • Oncology
|